Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Cagrilintide/semaglutide

CagriSema

Stage RegistrationStale

Sponsor Novo Nordisk A/S

Route injection

Class Amylin combo

Mechanism long-acting amylin analogue plus GLP-1 receptor agonist

Target amylin (TEC-0022)

Target GLP-1 receptor

Sources

company_release, as of 2025-12-18Stale

https://www.novonordisk-us.com/media/press-releases/novo-nordisk-cagrisema-fda-nda-submission.html

Novo Nordisk announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and the GLP-1 receptor agonist, semaglutide 2.4 mg.

Novo Nordisk U.S. press release dated Dec. 18, 2025

publication, as of 2025-06-22Stale

https://pubmed.ncbi.nlm.nih.gov/40544433/

The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).

N Engl J Med 2025;393:635-647, PMID 40544433, abstract

registry, as of 2026-09-30Stale

https://clinicaltrials.gov/study/NCT05567796

Protocol section, NCT05567796 REDEFINE 1, last update posted 2026-09-30

registry, as of 2026-09-30Stale

https://clinicaltrials.gov/study/NCT07564414

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 2500. Conditions Obesity; Type 2 Diabetes. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participan

ClinicalTrials.gov NCT07564414 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07919405

A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1408. Conditions Hypertension; Obesity. This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investiga

ClinicalTrials.gov NCT07919405 protocol and results modules

registry, as of 2026-01-28Stale

https://clinicaltrials.gov/study/NCT05394519

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1200. Conditions Overweight; Obesity; Type 2 Diabetes Mellitus. This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½

ClinicalTrials.gov NCT05394519 protocol and results modules

registry, as of 2026-02-06Stale

https://clinicaltrials.gov/study/NCT06131437

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 809. Conditions Obesity. This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant

ClinicalTrials.gov NCT06131437 protocol and results modules

registry, as of 2026-09-30Stale

https://clinicaltrials.gov/study/NCT07011667

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 609. Conditions Obesity. This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants

ClinicalTrials.gov NCT07011667 protocol and results modules

registry, as of 2026-09-30Stale

https://clinicaltrials.gov/study/NCT07253285

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 460. Conditions Overweight; Obesity. This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study

ClinicalTrials.gov NCT07253285 protocol and results modules

registry, as of 2026-01-20Stale

https://clinicaltrials.gov/study/NCT06780449

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 400. Conditions Obesity. This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and

ClinicalTrials.gov NCT06780449 protocol and results modules

registry, as of 2026-01-22Stale

https://clinicaltrials.gov/study/NCT05813925

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 331. Conditions Obesity or Overweight. This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in th

ClinicalTrials.gov NCT05813925 protocol and results modules

registry, as of 2026-05-05Stale

https://clinicaltrials.gov/study/NCT06388187

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity. This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get

ClinicalTrials.gov NCT06388187 protocol and results modules

registry, as of 2026-01-09Stale

https://clinicaltrials.gov/study/NCT05996848

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 300. Conditions Obesity or Overweight. This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants g

ClinicalTrials.gov NCT05996848 protocol and results modules

registry, as of 2026-09-04Stale

https://clinicaltrials.gov/study/NCT07745504

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 285. Conditions Overweight; Obesity. The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active m

ClinicalTrials.gov NCT07745504 protocol and results modules

registry, as of 2026-07-09Stale

https://clinicaltrials.gov/study/NCT07357766

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight. Overall status WITHDRAWN. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 0. Conditions Overweight; Obesity. This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of Cagri

ClinicalTrials.gov NCT07357766 protocol and results modules

registry, as of 2026-09-24Stale

https://clinicaltrials.gov/study/NCT06131372

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo. Overall status COMPLETED. Phases PHASE2. Lead sponsor Novo Nordisk A/S. Enrollment 626. Conditions Chronic Kidney Disease; Type 2 Diabetes; Obesity. This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to

ClinicalTrials.gov NCT06131372 protocol and results modules

registry, as of 2026-06-26Stale

https://clinicaltrials.gov/study/NCT07597018

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 234. Conditions Obesity; Overweight. This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintid

ClinicalTrials.gov NCT07597018 protocol and results modules

registry, as of 2026-01-08Stale

https://clinicaltrials.gov/study/NCT06267092

A Study of How CagriSema Works on Appetite in People With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 164. Conditions Overweight; Obesity. Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. Participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss m

ClinicalTrials.gov NCT06267092 protocol and results modules

registry, as of 2026-09-10Stale

https://clinicaltrials.gov/study/NCT07010432

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism. Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 144. Conditions Obesity. In this study we will investigate how the medicine cagrilintide affects bone health in women after menopause with obesity during weight loss, compared to treatment with placebo (the dummy medicine with no active substances) and semaglutide. The purpose is to examine whether cagri

ClinicalTrials.gov NCT07010432 protocol and results modules

registry, as of 2026-05-07Stale

https://clinicaltrials.gov/study/NCT07527195

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health). Overall status RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 100. Conditions Obesity. The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants wil

ClinicalTrials.gov NCT07527195 protocol and results modules

registry, as of 2026-09-10Stale

https://clinicaltrials.gov/study/NCT07184086

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 80. Conditions Obesity. In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been teste

ClinicalTrials.gov NCT07184086 protocol and results modules

registry, as of 2026-01-08Stale

https://clinicaltrials.gov/study/NCT06207877

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 62. Conditions Obesity. This research study tests if CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight. Participant will either get CagriSema (active medicine) or placebo (a dummy medicine), which has no effect on the body. The treatment participant

ClinicalTrials.gov NCT06207877 protocol and results modules

registry, as of 2025-12-12Stale

https://clinicaltrials.gov/study/NCT04940078

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity. Overall status COMPLETED. Phases PHASE1. Lead sponsor Novo Nordisk A/S. Enrollment 40. Conditions Obesity & Overweight. This study will compare two different ways of giving cagrilintide and semaglutide for treating overweight and obesity. The medicines will either be given together in 1 injection or as 2 separate injections. The aim of the study is to find out how the different ways of injection

ClinicalTrials.gov NCT04940078 protocol and results modules

Studies

REDEFINE 1

Registry NCT05567796

Phase Phase 3

Status Active, not recruiting

Enrollment 3400

Start 2022-11-01

Primary completion 2024-10-30

Study completion 2026-10-19

Catalyst Study completion. 2026-10-19Stale

Cagrisema

Dose cagrilintide 2.4 mg and semaglutide 2.4 mg

Regimen once weekly

Weeks 68

Comparator placebo

Population adults with obesity, or overweight with at least one obesity-related complication, without diabetes

percent change in body weight, -20.4 %, week 68Stale

estimated difference in percent change in body weight, -17.3 percentage points, week 68, vs placeboStale

Cagrilintide

Semaglutide

Placebo s.c.

Weeks 68

Population adults with obesity, or overweight with at least one obesity-related complication, without diabetes

percent change in body weight, -3 %, week 68Stale

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Registry NCT07564414

Phase Phase 3

Status Recruiting

Enrollment 2500

Start 2026-05-21

Primary completion 2028-02-23

Study completion 2028-04-19

Catalyst Primary completion. 2028-02-23. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrisema - dose level 1

Regimen once weekly

Weeks 83

Population Obesity; Type 2 Diabetes

Cagrisema - dose level 2

Regimen once weekly

Weeks 83

Population Obesity; Type 2 Diabetes

Semaglutide

Regimen once weekly

Weeks 83

Population Obesity; Type 2 Diabetes

REDEFINE

Registry NCT07919405

Phase Phase 3

Status Not yet recruiting

Enrollment 1408

Start 2026-11-11

Primary completion 2028-06-01

Study completion 2028-07-13

Catalyst Primary completion. 2028-06-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

CagriSema

Regimen once weekly

Comparator placebo

Population Hypertension; Obesity

Semaglutide

Regimen once weekly

Comparator placebo

Population Hypertension; Obesity

Cagrilintide

Regimen once weekly

Comparator placebo

Population Hypertension; Obesity

Placebo

Regimen once weekly

Population Hypertension; Obesity

REDEFINE 2

Registry NCT05394519

EudraCT 2021-005121-24

Phase Phase 3

Status Completed

Enrollment 1200

Start 2023-02-01

Primary completion 2025-01-28

Study completion 2025-02-03

Catalyst Primary completion. 2025-01-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Comparator placebo

Population Overweight; Obesity; Type 2 Diabetes Mellitus

Placebo

Regimen once weekly

Population Overweight; Obesity; Type 2 Diabetes Mellitus

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Registry NCT06131437

Phase Phase 3

Status Completed

Enrollment 809

Start 2023-11-27

Primary completion 2025-12-08

Study completion 2026-01-09

Catalyst Primary completion. 2025-12-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema 2.4 mg/2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 16

Population Obesity

Tirzepatide 15 mg

Dose 15 mg

Regimen once weekly

Weeks 16

Population Obesity

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Registry NCT07011667

Phase Phase 3

Status Active, not recruiting

Enrollment 609

Start 2025-06-03

Primary completion 2027-03-01

Study completion 2028-10-17

Catalyst Primary completion. 2027-03-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 4

Population Obesity

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Registry NCT07253285

Phase Phase 3

Status Recruiting

Enrollment 460

Start 2026-01-08

Primary completion 2030-03-20

Study completion 2033-09-20

Catalyst Primary completion. 2030-03-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 16

Comparator placebo

Population Overweight; Obesity

Semaglutide

Regimen once weekly

Weeks 16

Comparator placebo

Population Overweight; Obesity

Cagrilintide

Regimen once weekly

Weeks 16

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once weekly

Weeks 16

Population Overweight; Obesity

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Registry NCT06780449

Phase Phase 3

Status Active, not recruiting

Enrollment 400

Start 2025-02-10

Primary completion 2028-08-28

Study completion 2028-10-31

Catalyst Primary completion. 2028-08-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 16

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 16

Population Obesity

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Registry NCT05813925

Phase Phase 3

Status Completed

Enrollment 331

Start 2023-04-03

Primary completion 2025-01-17

Study completion 2025-03-07

Catalyst Primary completion. 2025-01-17. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema 2.4 mg/2.4 mg

Dose 2.4 mg

Regimen once weekly

Population Obesity or Overweight

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Population Obesity or Overweight

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Registry NCT06388187

Phase Phase 3

Status Completed

Enrollment 300

Start 2024-06-24

Primary completion 2026-04-22

Study completion 2026-04-22

Catalyst Primary completion. 2026-04-22. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema Dose 1

Regimen once weekly

Weeks 60

Comparator placebo

Population Obesity

Placebo Dose 1

Regimen once weekly

Weeks 60

Population Obesity

CagriSema Dose 2

Regimen once weekly

Weeks 60

Comparator placebo

Population Obesity

Placebo Dose 2

Regimen once weekly

Weeks 60

Population Obesity

REDEFINE 6

Registry NCT05996848

Phase Phase 3

Status Completed

Enrollment 300

Start 2023-08-15

Primary completion 2025-01-06

Study completion 2025-02-22

Catalyst Primary completion. 2025-01-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 44

Comparator placebo

Population Obesity or Overweight

Semaglutide

Regimen once weekly

Weeks 44

Comparator placebo

Population Obesity or Overweight

Placebo

Regimen once weekly

Weeks 44

Population Obesity or Overweight

RENEW 4

Registry NCT07745504

Phase Phase 3

Status Recruiting

Enrollment 285

Start 2026-08-04

Primary completion 2027-05-18

Study completion 2027-07-06

Catalyst Primary completion. 2027-05-18. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide + placebo semaglutide in device 1 and placebo cagrilintide in device 2

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1

Regimen once weekly

Weeks 26

Population Overweight; Obesity

Placebo cagrilintide in device 2 and placebo cagrilintide + placebo semaglutide in device 1

Regimen once weekly

Weeks 26

Population Overweight; Obesity

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

Registry NCT07357766

Phase Phase 3

Status Withdrawn

Enrollment 0

Start 2026-06-22

Primary completion 2027-11-29

Study completion 2028-01-17

Catalyst Primary completion. 2027-11-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema B in device 2 + Placebo in device 1

Regimen once weekly

Weeks 16

Population Overweight; Obesity

CagriSema in device 1 + Placebo in device 2

Regimen once weekly

Weeks 16

Population Overweight; Obesity

Placebo in device 1 + Placebo in device 2

Regimen once weekly

Weeks 16

Population Overweight; Obesity

A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglu

Registry NCT06131372

EudraCT 2023-505857-42

Phase Phase 2

Status Completed

Enrollment 626

Start 2024-04-01

Primary completion 2025-09-24

Study completion 2025-11-06

Catalyst Primary completion. 2025-09-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 35

Comparator placebo

Population Chronic Kidney Disease; Type 2 Diabetes; Obesity

Semaglutide

Regimen once weekly

Weeks 35

Comparator placebo

Population Chronic Kidney Disease; Type 2 Diabetes; Obesity

Cagrilintide

Regimen once weekly

Weeks 35

Comparator placebo

Population Chronic Kidney Disease; Type 2 Diabetes; Obesity

Placebo

Regimen once weekly

Weeks 35

Population Chronic Kidney Disease; Type 2 Diabetes; Obesity

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

Registry NCT07597018

Phase Phase 1

Status Recruiting

Enrollment 234

Start 2026-05-18

Primary completion 2027-05-28

Study completion 2027-06-01

Catalyst Primary completion. 2027-05-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide B and Placebo Semaglutide I

Regimen once weekly

Weeks 17

Population Obesity; Overweight

Cagrilintide D-Injection site 1

Regimen once weekly

Weeks 17

Comparator placebo

Population Obesity; Overweight

Cagrilintide D-Injection site 2

Regimen once weekly

Weeks 17

Comparator placebo

Population Obesity; Overweight

Cagrilintide D-Injection site 3

Regimen once weekly

Weeks 17

Comparator placebo

Population Obesity; Overweight

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Registry NCT06267092

Phase Phase 1

Status Completed

Enrollment 164

Start 2024-02-15

Primary completion 2025-04-07

Study completion 2025-12-08

Catalyst Primary completion. 2025-04-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Part A

Population Overweight; Obesity

Part B

Population Overweight; Obesity

RAMBO

Registry NCT07010432

Phase Phase 1

Status Recruiting

Enrollment 144

Start 2025-06-12

Primary completion 2028-05-03

Study completion 2028-05-03

Catalyst Primary completion. 2028-05-03. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cagrilintide

Regimen once weekly

Weeks 79

Comparator placebo

Population Obesity

Semaglutide

Regimen once weekly

Weeks 79

Comparator placebo

Population Obesity

CagriSema

Regimen once weekly

Weeks 79

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 79

Population Obesity

RASMUS

Registry NCT07527195

Phase Phase 1

Status Recruiting

Enrollment 100

Start 2026-04-10

Primary completion 2028-04-28

Study completion 2028-06-09

Catalyst Primary completion. 2028-04-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity

Semaglutide

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity

Cagrilintide

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 52

Population Obesity

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

Registry NCT07184086

Phase Phase 1

Status Active, not recruiting

Enrollment 80

Start 2025-09-26

Primary completion 2027-10-12

Study completion 2028-02-09

Catalyst Primary completion. 2027-10-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

CagriSema (Cagrilintide + Semaglutide) / CagriSema

Population Obesity

Low Energy Diet (LED) / CagriSema

Population Obesity

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Registry NCT06207877

Phase Phase 1

Status Completed

Enrollment 62

Start 2024-02-23

Primary completion 2024-10-16

Study completion 2024-11-22

CagriSema

Regimen once weekly

Weeks 32

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Weeks 32

Population Obesity

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Registry NCT04940078

Phase Phase 1

Status Completed

Enrollment 40

Start 2021-07-07

Primary completion 2022-01-19

Study completion 2022-02-16

Part A: Cagrilintide and semaglutide in separate syringes

Regimen every 4 weeks

Weeks 14

Population Obesity & Overweight

Part A: Cagrilintide and semaglutide combined in DV3384 device

Regimen every 4 weeks

Weeks 14

Population Obesity & Overweight

Part B: Cagrilintide and semaglutide combined in DV3384 device

Regimen once weekly

Weeks 14

Population Obesity & Overweight

Catalyst NDA submitted for weight management. The Dec. 18, 2025 release says the NDA was submitted and says if approved. It does not state a decision date.Stale